1/ Flecainide monotherapy: Risks you need to know ⚡💊
While effective for rhythm control, flecainide carries serious risks—especially when used without an AV nodal blocker. Here’s why. 🧵👇
#Cardiology#AtrialFibrillation#Flecainide
Thank you so much Dr. Hahn @hahn_rt
Now volume 2 of the series is also available free of cost online. Both volumes (1 & 2) can be downloaded at: cardiotextpublishing.com/ope…
Among patients with ventricular tachycardia and ischemic cardiomyopathy, catheter ablation as an initial therapy led to a lower risk of adverse outcomes than antiarrhythmic drug therapy. Read the full VANISH2 trial results: nej.md/3Z5ECOD#cardiology
ALT Kaplan–Meier analysis of the primary end point.
Congratulations to @johnlsapp on the presentation and publication of VANISH-2.
First line VT ablation is associated with significant reduction in composite of death, VT, storm for patients with ischemic cardiomyopathy.
nejm.org/doi/full/10.1056/NE…
New 2024 #ESCGuidelines on #Afib
🆕Class IA recommendation:
Catheter ablation for AF now recommended as a first-line option within a shared decision-making rhythm control strategy in paroxysmal AF
#ESCCongress@escardio
Atrial Cardiomyopathy Revisted- Evolution of a Concept. A Clinical Consensus Statement of the (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Association (APHRS), and the Latin American Heart Rhythm Society (LAHRS)
lnkd.in/dVrG2STT
It has been an honor to be part of the international electrophysiology education program #BeEP over the last 5 years.
Highly recommend #BeEP for future #EPFellows!
„It is the lives we encounter that make life worth living.“
@DavidHayesMD@iwalux_77@BIOTRONIK_News